CAS: 1759-28-0; 4-Methyl-5-Vinylthiazole

上下游产品

5-hydroxyethyl-4-methylthiazole chlormethiazole 5-(2-bromoethyl)-4-methyl-1,3-thiazole 1vitamin B1 tert-butyl ester[1-[4-(4-methoxy-2,3,6-trimethyl-benzenesulfonylamino)-cyclohexyl]-2-(4-methyl-5-vinyl-thiazol-2-yl)-2-oxo-ethyl]-carbamic acid tert-butyl ester 4-methyl-5-ethylthiazole 5-(endo-bicyclo[2.2.1]hept-5-en-2-yl)-4-methyl-1,3-thiazole 5-(exo-bicyclo[2.2.1]hept-5-en-2-yl)-4-methyl-1,3-thiazole

5-(2-Bromoethyl)-4-Methylthiazole置于silver(L) Oxide体系中,用 苯 用作溶剂,化学反应 13.0H,反应生成4-甲基-5-乙烯基噻唑
参考文献:芳基烯烃存在下芳族和杂芳族氮衍生物的光化学反应性
标题:芳基烯烃存在下芳族和杂芳族氮衍生物的光化学反应性
摘要:在硝基芳烃存在下于乙腈中对苯乙烯进行辐照,可以高收率得到相应的硝酮.然而,当使用4-甲基-5-乙烯基噻唑作为芳基烯烃时,起始原料被转化为类似于噻吩的吡咯.相反,当使用1,1-二苯乙烯时,观测到的主要产物是二苯甲酮.硝酸盐仅作为次要产品获得.还获得了不寻常的偶合产物,其中在带有硝基的碳上发生了取代反应.反式-二苯乙烯在相同的光化学条件下不反应,仅苯甲醛的收率低.最后,当使用芳族硝基衍生物时,茚仅产生氧化产物,而当使用杂芳族硝基衍生物时,仅观测到硝基上的取代产物.可以通过使用试剂前沿轨道上的am1半经验计算结果来解释上述反应性.硝基芳烃的lsomo的性质和试剂的偶极矩均可解释观测到的反应性.在苯乙烯和硝基苯之间的光化学反应中获得的硝酮用作与苯乙烯的1,3-偶极环加成反应的起始原料.
Doi:10.1016/0040-4020(96)00878-2

专利信息

专利号:US-6683191-B2
优先权日:2000-06-05
标 题:Method for synthesis of substituted azole libraries
发明人：DENG YIJUN; HLASTA DENNIS
权利人:ORTHO MCNEIL PHARM INC
摘要:The invention relates to methods of synthesizing libraries of diverse and complex 2-substituted azole compounds of the general formula (I) or (II)wherein X, R<2 >and the ring componentsare as described herein, novel intermediates useful for synthesizing such substituted azole compounds and methods for identifying and isolating the compounds.

专利号:WO-0194318-A2
优先权日:2000-06-05
标题 :Method for synthesis of substituted azole libraries

专利号:US-2002077483-A1
优先权日:2000-06-05
标题 :Method for synthesis of substituted azole libraries

专利号:US-2002042520-A1
优先权日:2000-06-05
标 题:Method for synthesis of substituted azole libraries

专利号:WO-0194317-A2
优先权日:2000-06-05
标 题:Method for synthesis of substituted azole libraries

专利号:US-7671085-B2
优先权日:2002-11-15
标 题 :Non-steroidal farnesoid X receptor modulators and methods for the use thereof
发明人：DOWNES MICHAEL R; EVANS RONALD M
权利人:SALK INST FOR BIOLOGICAL STUDI
摘要:The efficient regulation of cholesterol synthesis, metabolism, acquisition, and transport is an essential component of lipid homeostasis. The farnesoid X receptor (FXR) is a transcriptional sensor for bile acids, the primary product of cholesterol metabolism. Accordingly, the development of potent, selective, small molecule agonists, partial agonists, and antagonists of FXR would be an important step in further deconvoluting FXR physiology. In accordance with the present invention, the identification of novel potent FXR activators is described. Two derivatives of invention compounds, bearing stilbene or biaryl moieties, contain members that are the most potent FXR agonists reported to date in cell-based assays. These compounds are useful as chemical tools to further define the physiological role of FXR as well as therapeutic leads for the treatment of diseases linked to cholesterol, bile acids and their metabolism and homeostasis.